Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AXSM | CLUSTER | neutral | 4/10 | CEO Herriot and CFO Pizzie exercised stock options and immediately sold the resulting shares in open-market transactions | Jun 9, 2026 |
| ENVB | 8-K | bearish | 6/10 | Enveric Biosciences filed a prospectus supplement to offer up to $2,425,000 of common stock under its existing ATM agree | Jun 9, 2026 |
| IDYA | 424B5 | bearish | 6/10 | IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares | Jun 9, 2026 |
| PTCT | 8-K | neutral | 2/10 | Board member Alethia Young resigned effective June 8, 2026, citing a need to focus on other work commitments, with no di | Jun 9, 2026 |
| STTK | 424B5 | bearish | 6/10 | Shattuck Labs filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-fund | Jun 9, 2026 |
| ENVB | 424B5 | bearish | 7/10 | Enveric Biosciences filed a 424B5 prospectus supplement to increase its ATM offering capacity by up to $2,425,000, bring | Jun 9, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK plc filed a 6-K disclosing that Non-Executive Director Dr. Hal Barron was appointed as an Independent Director and C | Jun 9, 2026 |
| KYNB | 8-K | neutral | 2/10 | Kyntra Bio received the final $4.0 million holdback from AstraZeneca related to the August 2025 sale of its China operat | Jun 9, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, wit | Jun 9, 2026 |
| GLPGF | 6-K | neutral | 4/10 | Lakefront Biotherapeutics (formerly Galapagos) announced a $50 million share repurchase program, authorized through Dece | Jun 9, 2026 |
| MBX | 144 | bearish | 5/10 | Richard Bartram, a former officer of MBX Biosciences, filed a Form 144 notice of intent to sell 10,833 shares of common | Jun 9, 2026 |
| AKAN | 20-F | bearish | 8/10 | Akanda Corp. filed its FY2025 20-F, resolving the Nasdaq deficiency notice from May 2026 related to the late filing, but | Jun 9, 2026 |
| CLLS | 6-K | bullish | 7/10 | Cellectis announced FDA Regenerative Medicine Advanced Therapy (RMAT) designation for lasme-cel, its allogeneic CAR-T th | Jun 9, 2026 |
| SMMT | S-3ASR | bearish | 7/10 | Summit Therapeutics filed an S-3ASR shelf registration on June 9, 2026, with no specified offering size or pricing, allo | Jun 9, 2026 |
| ADTX | 8-K | bearish | 7/10 | Aditxt entered into a Note Purchase Agreement on June 3, 2026, issuing $725,000 in new senior secured notes (plus rollov | Jun 9, 2026 |
| STTK | 8-K | bullish | 6/10 | Shattuck Labs announced positive Phase 1 data for SL-325 (DR3 blocking antibody) showing low immunogenicity (3.7% ADA), | Jun 9, 2026 |
| HRMY | 144 | neutral | 3/10 | Former officer Sandip Kapadia filed a Form 144 notice of intent to sell up to 27,960 shares (~$943K at recent prices), a | Jun 9, 2026 |
| IVEVF | 6-K | neutral | 3/10 | Inventiva S.A. filed a 6-K announcing the availability of preparatory documents for its Combined General Meeting on June | Jun 9, 2026 |
| VGASW | DEFA14A | neutral | 2/10 | Verde Clean Fuels filed a DEFA14A supplement to its definitive proxy statement, disclosing that director Martijn Dekker | Jun 9, 2026 |
| VGASW | 8-K | neutral | 2/10 | Director Martijn Dekker resigned from the Board of Directors effective June 3, 2026. The filing provides no reason, repl | Jun 9, 2026 |
| IPSC | CLUSTER | neutral | 2/10 | Two insiders at Century Therapeutics sold small open-market positions totaling ~$1.6K on June 8, 2026, while the CEO had | Jun 9, 2026 |
| CYCN | S-4/A | bearish | 7/10 | Cyclerion Therapeutics files S-4/A for reverse merger with Korsana Biosciences. Current CYCN shareholders will own ~1.5% | Jun 9, 2026 |
| VRCA | 8-K | neutral | 3/10 | Verrica Pharmaceuticals filed an 8-K reporting that stockholders approved the Amended and Restated 2018 Equity Incentive | Jun 9, 2026 |
| JSPRW | 8-K | bearish | 7/10 | Jasper Therapeutics received a Nasdaq deficiency notice on June 3, 2026, because its common stock bid price closed below | Jun 9, 2026 |
| ARQT | 8-K | neutral | 2/10 | Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three p | Jun 9, 2026 |
| ESPR | 8-K | bullish | 6/10 | Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the pending acquisition | Jun 9, 2026 |
| TVGN | PRESS-RELEASE | neutral | 5/10 | Tevogen Bio announced a healthcare services initiative exploring potential acquisitions of a Management Services Organiz | Jun 9, 2026 |
| IFF | ANALYST-UPGRADE | bullish | 3/10 | Benchmark initiated coverage on IFF at Buy with a $100 price target, implying 36% upside from the current $73.56 close. | Jun 9, 2026 |
| NRSNW | 6-K | neutral | 4/10 | NeuroSense Therapeutics received a Japanese patent (No. 7857044) for its lead ALS drug candidate PrimeC, extending intel | Jun 9, 2026 |
| BAK | 6-K | mixed | 6/10 | Braskem S.A. held an Extraordinary General Meeting on June 8, 2026, approving the election of a new Board of Directors a | Jun 9, 2026 |